AI in the pharmaceutical industry: use cases, risks and regulation

Artificial intelligence is already at work in pharmaceutical plants, but rarely where people imagine it. It does not reinvent the molecule on the line: it reads serialisation codes, re-reads batch records, retrieves a deviation five years old and watches the drift of a water-for-injection loop. Everywhere, it speeds up work that a human was already doing, without ever carrying the regulated decision in the place of whoever answers for it.

That last point is what sets pharma apart from almost every other sector. Here, no tool is deployed without validation, and no AI signs a batch release. The framework, good manufacturing practice (GMP), Annex 11, 21 CFR Part 11, data integrity, cannot be sidestepped: it decides what is deployable before performance even enters the conversation.

Visual inspection of packaging and serialisation

On packaging lines, computer vision checks what the eye struggles to watch at full speed: the presence and integrity of the leaflet, the legibility of a print, the conformity of a blister, the presence of a tamper-evident seal, the reading of the DataMatrix serialisation and aggregation codes required for traceability. For every decision, an image is kept, which turns a check into replayable evidence. It is the same principle described for AI visual quality inspection: the machine is not smarter than a good operator, it is simply immune to what erodes their attention.

Honest limit: a vision model drifts as soon as the format, the lighting or a new reference changes. It needs a representative image set, a confidence threshold that returns the ambiguous case to a human, and follow-up. Above all, the model itself becomes a component to validate and version, exactly like the rest of the line.

Assisted batch-record review

Releasing a batch means re-reading a file that is sometimes thick: manufacturing orders, in-process controls, analytical results, out-of-sequence deviations. AI can prepare this review by exception: it reconciles MES and LIMS data with the paper record, flags a missing signature, a step out of order, an out-of-specification value, a blank to fill. The reviewer no longer starts from a blank page, they start from a list of points to settle. The release cycle shortens without any drop in vigilance.

Honest limit: AI flags, it does not clear. It can miss a context a pharmacist would have seen, and produce false alerts that cost time. Responsibility for the review and the release stays whole and human, exactly as the line between preparing and deciding makes clear. AI reduces the volume of routine checks, not the weight of the decision.

Documentary intelligence for deviations, CAPAs and archives

A pharmaceutical site accumulates years of deviations, corrective and preventive actions (CAPAs), complaints and change controls, often frozen in PDFs that nobody re-reads. Documentary intelligence reads these documents, extracts their meaning and makes them searchable: retrieving every deviation linked to a piece of equipment or a product, spotting a cause that recurs, reconstructing the history of a discrepancy becomes a matter of seconds. It is also what saves days when you have to prepare a quality audit without chasing evidence. Software such as Integrity Loop belongs to this family: it reads and structures existing inspection and production reports, deviations and batch records included, to make them usable, without being a predictive-maintenance tool.

Honest limit: search by meaning brings together what looks alike, it does not certify validity. A document that has been found may be expired or cover an earlier version of a procedure. The quality team checks each item, and the integrity of the source archive stays a prerequisite: an AI plugged into doubtful data returns doubtful answers.

Predictive monitoring of sterile utilities

Away from the lines, AI watches the utilities that underpin sterility: purified-water and water-for-injection (WFI) loops, cleanroom air handling (differential pressure, particle counts, temperature and humidity), sterilisers, compressed air. By reading the signals of these systems, a model flags a drift before it becomes an excursion, the kind that would jeopardise a batch or trigger an environmental-monitoring deviation.

Honest limit: predictive monitoring is only as good as the historised data. A prediction is an alert to investigate, never an automatic action on a GMP-critical utility. Any parameter change stays under change control, and a statistical alert does not replace a qualified alarm limit.

Risks and regulation: what really decides the deployment

The difficulty of AI in pharma is not the algorithm, it is proving it under a framework built for computerised systems long before machine learning. An AI feature escapes none of these obligations: it inherits them.

GMP, Annex 11 and 21 CFR Part 11. Annex 11 of EU GMP governs computerised systems used in a GMP environment; the FDA's 21 CFR Part 11 governs electronic records and signatures. Both demand validated systems, a reliable audit trail, controlled access and attributable records. An AI brick that produces or transforms a record falls squarely within that scope.

Data integrity, ALCOA+. A data point must stay Attributable, Legible, Contemporaneous, Original and Accurate, rounded out by the Complete, Consistent, Enduring and Available criteria. An AI that scores, classifies or rephrases a data point must preserve the original and record what, who and when. A score with no provenance cannot be defended in front of an inspector.

Computerised system validation and GAMP 5. The risk-based GAMP 5 approach applies to the model itself: its training data, its version and its changes must be documented and frozen. A retraining is a change to control, and you must be able to replay a past decision. The model stops being a mere file: it becomes a validated, versioned artefact.

Explainability and the "black box" effect. A model unable to justify its output is a compliance problem before it is a technical one. In a regulated environment, you favour setups whose decision can be explained, traced and audited, even at the cost of giving up a more capable but opaque model.

Who signs. None of these use cases shifts responsibility. AI prepares, filters, alerts and documents; the release, the acceptance of a deviation and the signature stay carried by the responsible pharmacist. It is the principle that runs through every serious use of industrial AI: it prepares the decision, it does not take it.

Summary table

Table scrolls horizontally on small screens.

Support on the quality and compliance side

What sinks most projects is not the model, it is its integration into a quality system: data preparation, validation, audit trail, reversibility. That is the work of Assets 4.0, the industrial-AI engineering group that publishes this blog, whose quality and compliance AI solutions are aimed precisely at regulated environments. The principle stays the same from end to end: scope a specific use, demonstrate it on your own documents with their flaws, and check that it can be validated before you sign.

What to take away

In pharma, AI saves time where the work is repetitive and verifiable: it sees without tiring, re-reads without being distracted, retrieves without forgetting, and monitors without sleeping. Its value lies in consistency and the trail, not in judgement. And because the sector requires that everything be validated, traced and reproducible, the model itself becomes a regulated artefact. The red line does not move: AI prepares the responsible pharmacist's decision, it never releases in their place.